Artwork

Content provided by The Radcliffe Cardiology Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Radcliffe Cardiology Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

View from the Thoraxcenter: AHA 23 Late-breaking Science Wrap Up

23:14
 
Share
 

Manage episode 384812165 series 2990303
Content provided by The Radcliffe Cardiology Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Radcliffe Cardiology Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
What's hot at #AHA23? Join Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) as they review the latest late-breaking science data from AHA Scientific Sessions 2023. They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research. Trials Covered include: 00:20 - DAPA-MI: Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack 06:30 - ORBITA-2: Percutaneous Coronary Intervention for Stable Angina: A Randomised, Placebo-Controlled Trial 12:39 - A Sub-Analysis of the Prospective ECLS-Shock Trial 16:13 - ARTESiA: Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation 10:02 - SELECT: Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity Who Do Not Have Diabetes We value your opinion! Share your feedback by commenting on this page or sending us an email at info@radcliffe-group.com.
  continue reading

36 episodes

Artwork
iconShare
 
Manage episode 384812165 series 2990303
Content provided by The Radcliffe Cardiology Podcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Radcliffe Cardiology Podcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
What's hot at #AHA23? Join Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) as they review the latest late-breaking science data from AHA Scientific Sessions 2023. They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research. Trials Covered include: 00:20 - DAPA-MI: Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack 06:30 - ORBITA-2: Percutaneous Coronary Intervention for Stable Angina: A Randomised, Placebo-Controlled Trial 12:39 - A Sub-Analysis of the Prospective ECLS-Shock Trial 16:13 - ARTESiA: Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation 10:02 - SELECT: Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity Who Do Not Have Diabetes We value your opinion! Share your feedback by commenting on this page or sending us an email at info@radcliffe-group.com.
  continue reading

36 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide